Clinical trial · Interventional
Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer
Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Endoscopic Ultrasonography-guided Sampling of Suspected Unresectable Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: Pancreatic cancer is associated with a poor prognosis. Therefore, rapid and accurate diagnosis of a pancreatic mass is important to direct patient management. Endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) is the current standard for sampling pancreatic mass lesions, with diagnostic accuracy of 78% to 95%. But, the EUS-FNA has some limitations include stromal cell tumors and lymphomas may be difficult to diagnose. To overcome these limitations, a new needle device with ProCore reverse-bevel technology was developed recently. Aims: The objective of this prospective study is to compare the rate of diagnostic sufficiency in the EUS sampling by using newly developed ProCore needle with conventional FNA needle in suspected unresectable pancreatic cancer. We will also compare the safety, the yield of histologic core tissue and the cost-effectiveness between these modalities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 22 gauge Fine needle aspiration | Device | — | UNRESOLVED |
| 22 gauge ProCore needle aspiration | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 22 gauge ProCore needle aspiration
- description
- EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
- interventionNames
- Device: 22 gauge ProCore needle aspiration
- type
- ACTIVE_COMPARATOR
- label
- 22 gauge Fine needle aspiration
- description
- EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
- interventionNames
- Device: 22 gauge Fine needle aspiration
Primary outcomes (1)
- measure
- The rates of diagnostic sufficiency
- timeFrame
- Up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who agree to participate in research * 18 years of age and older patients less than 80 years old * Patients who have suspected unresectable pancreatic cancer in imaging studies Exclusion Criteria: * Contraindication to endoscopy * Patients younger than 18 years old or older than 80 years old * Bleeding tendency * Cardiopulmonary dysfunction * Pregnancy
References
Publications (0)
Data not yet available